Protocols
5 protocol(s) meet the specified criteria
Drug: PEMBROLIZUMAB
Protocol No.TitleStatus
2401BT-002PA Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) with Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or GliosarcomaOpen
GI15-225A pilot study of pembrolizumab in combination with Y90 radioembolization in patients with high risk hepatocellular carcinoma with preserved liver functionOpen
J1651Phase 2 Study of Azacitidine (AZA) in Combination with Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (>65 Years) AML PatientsOpen
LCCC1620Phase 2 Study of Denosumab in Combination with a PD-1 Inhibitor in Patients with Unresectable Stage III/IV Cutaneous MelanomaOpen
SGN22E-002A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancerOpen